For MTX-E1, Montara Therapeutics is pairing the approved medicine everolimus with a second molecule intended to keep its activity out of peripheral tissues. The aim is to preserve the drug’s neurological benefit while reducing systemic effects that limit treatment. A successful combination could let CNS developers revisit compounds whose usefulness has been limited by toxicity.
A development strategy built around selective activity
BrainOnly, Montara’s platform, combines a therapeutic that enters the brain with a blocker designed to stay outside it. The company puts the blood-brain barrier’s separation to work, using it to control where pharmacology occurs rather than viewing it only as a delivery obstacle.
The lead blocker, MT1110, occupies FKBP12 binding sites outside the brain. Montara’s approach is intended to prevent drugs that depend on FKBP12 from acting in those tissues, while preserving their activity in the CNS. Its lead pairing combines MT1110 with everolimus for epilepsy associated with tuberous sclerosis complex, or TSC.
This changes the development question. The platform still has to deliver enough medicine to the brain at an exposure patients can tolerate. A wider therapeutic window could give developers room to reach useful brain concentrations with less peripheral toxicity.
Nicholas Hertz, Founder and CEO of Montara Therapeutics, describes how the same blocker could work with different BrainTAC therapeutics. Reusing a blocker across several programs is the commercial proposition: developers could avoid building a bespoke pair for every target. Each combination would still need its own evidence.
An approved drug provides a starting point, not a shortcut
MTX-E1 gives Montara a relatively grounded first test. Everolimus already treats TSC-related seizures, but systemic mTOR inhibition can cause immunosuppression and metabolic adverse effects. Montara aims to retain seizure control while limiting activity elsewhere.
Preclinical findings presented at the American Epilepsy Society Annual Meeting support further development. In a conditional Tsc1 knockout mouse model, the MT1110 combination improved seizure control relative to the same everolimus dose alone and reduced treatment-associated adverse effects. Human benefit remains unproven. Initial human studies are anticipated for early 2027.
Existing treatment combinations offer some precedent for separating central and peripheral effects. Hertz points to levodopa with carbidopa and Bristol Myers Squibb’s Cobenfy as examples of that broader principle. Montara’s proposed distinction is the ability to reuse its blocking technology across targets.
The familiarity of everolimus helps with regulatory development and eventual adoption, within limits. Developers can draw on its established pharmacology, but still need to establish the safety and efficacy of the new pairing. The evidence package will need to show what adding MT1110 changes.
Three questions should guide that assessment:
- Does peripheral blockade preserve clinically meaningful seizure control?
- Does it reduce the adverse effects that complicate existing treatment?
- Can the two components maintain the intended separation of activity at usable doses?
These are also the questions that would shape prescribing. A mechanistically elegant combination needs a clear clinical advantage over the medicine physicians already know.
Parkinson’s expands the opportunity and the evidence burden
The Michael J. Fox Foundation has provided approximately $1 million to support Montara’s brain-selective mTOR work for Parkinson’s disease. The company hopes that keeping mTOR inhibition in the brain will stimulate autophagy and help clear harmful alpha-synuclein aggregates, while avoiding systemic immunosuppression.
That program carries a different challenge from MTX-E1. Improving the tolerability of a therapy with established seizure activity is distinct from demonstrating that selective mTOR inhibition benefits Parkinson’s disease. The funding allows Montara to explore the mechanism, but the therapeutic outcome still needs validation.
Montara is also pursuing a brain-selective LRRK2 program with foundation support. Hertz identifies lung toxicity as a reason to develop blockers with stronger activity in particular organs. The company’s next-generation portfolio therefore moves beyond a single broadly distributed peripheral blocker toward tissue profiles matched to individual liabilities.
For potential pharma partners, that flexibility could be valuable. Toxicity-constrained targets may become more attractive if a blocker can address the relevant organ exposure. The opportunity depends on demonstrating that such protection is reliable without undermining the intended brain effect.
Clinical differentiation will determine platform value
Montara’s strongest near-term route is to establish a measurable advantage with MTX-E1 before treating broader platform potential as a competitive asset. Reduced peripheral toxicity, if demonstrated alongside sustained seizure control, could support adoption by making an existing treatment approach easier to use.
Success would give Montara a stronger rationale to test new targets and additional combinations. The immediate priority is human evidence that peripheral blockade delivers a better balance of neurological benefit and treatment burden. With that evidence, clinicians, partners, and regulators could assess subsequent programs on firmer ground.
